References

Description

- Bendelac, A., Savage, P. B., and Teyton, L. (2007) The Biology of NKT Cells. *Annu. Rev. Immunol*. **25**, 297â??336.
- Boes, M. (2000) Role of natural and immune IgM antibodies in immune responses. *Mol. Immunol.* **37**, 1141â??1149.
- Boland, C. R., and Ricciardiello, L. (1999) How many mutations does it take to make a tumor ? *Proc. Natl. Acad. Sci. U. S. A.* **96**, 14675â??14677.
- Cohn, M., Av Mitchison, N., Paul, W. E., Silverstein, A. M., Talmage, D. W., and Weigert, M. (2007) Reflections on the clonal-selection theory. *Nat Rev Immunol* **7**, 823â??830.
- Doria-Rose, N. A., and Joyce, M. G. (2015) Strategies to guide the antibody affinity maturation process. *Curr. Opin. Virol.* **11**, 137â??147.
- Freeman, S. A., JaumouillÃ©, V., Choi, K., Hsu, B. E., Wong, H. S., Abraham, L., Graves, M. L., Coombs, D., Roskelley, C. D., Das, R., Grinstein, S., and Gold, M. R. (2015) Toll-like receptor ligands sensitize B-cell receptor signalling by reducing actin-dependent spatial confinement of the receptor. *Nat. Commun.* **6**, 6168.
- Groscurth, P., and Filgueira, L. (1998) Killing Mechanisms of Cytotoxic T Lymphocytes. *Physiology* **13,** 17â??21.
- Kurts, C., Robinson, B. W. S., and Knolle, P. A. (2010) Cross-priming in health and disease. *Nat. Publ. Gr.* **10**, 403â??414.
- Iwasaki, A., and Medzhitov, R. (2010) Regulation of Adaptive Immunity by the Innate Immune System. *Science* . **327**, 291 LP-295.
- Nimmerjahn, F., and Ravetch, J. V. (2008) FcÎ³ receptors as regulators of immune responses. *Nat Rev Immunol* **8**, 34â??47.
- Rickert, R. C. (2005) Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. *Curr. Opin. Immunol*. **17**, 237â??243.
- Rosenberg, S. A., and Restifo, N. P. (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. *Science*. **348**, 62â??68.
- Stumbles, P. A., Himbeck, R., Frelinger, J. A., Collins, E. J., Lake, R. A., and Robinson, B. W. S. (2004) Cutting Edge : Tumor-Specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate to Mediate Tumor Regression following Systemic CD40 Activation. *J. Immunol.* **173**, 5923â??5928.